Evidence map›Paper›PMID 36621967›Full record

ArticleHuman molecular genetics2023

Dysregulation of the chromatin environment leads to differential alternative splicing as a mechanism of disease in a human model of autism spectrum disorder.

Calvin S Leung, Shoshana J Rosenzweig, Brian Yoon, Nicholas A Marinelli, Ethan W Hollingsworth, Abbie M Maguire, Mara H Cowen, Michael Schmidt, Jaime Imitola, Ece D Gamsiz Uzun and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Alternative splicing in addiction.Current opinion in genetics & development · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Calvin S LeungDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.
Shoshana J RosenzweigCenter for Computational Molecular Biology, Brown University, Providence, RI 02906, USA.
Brian YoonDepartment of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA.
Nicholas A MarinelliDepartment of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA.
Ethan W HollingsworthUCONN Health Comprehensive Multiple Sclerosis Center, Department of Neurology, University of Connecticut School of Medicine, Farmington, CT 06030, USA.
Abbie M MaguireDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.
Mara H CowenDepartment of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA.
Michael SchmidtDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.ORCID 0000-0002-7990-033X
Jaime ImitolaUCONN Health Comprehensive Multiple Sclerosis Center, Department of Neurology, University of Connecticut School of Medicine, Farmington, CT 06030, USA.
Ece D Gamsiz UzunCenter for Computational Molecular Biology, Brown University, Providence, RI 02906, USA.
Sofia B LizarragaDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.ORCID 0000-0001-5153-1993
Allen Institute for Brain Science · USUniversity of South Carolina · USBrown University · USUniversity of Connecticut · US

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
ASH1L mediated transcription networks in autism spectrum disordersR01MH127081 · NIMH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Judy Shih-Hwa Liu, Sofia Beatriz Lizarraga · 2022 to 2026
$4.7M
Postdoctoral Training in Reproductive Mood DisordersT32MH093315 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUSAN Scott GIRDLER, David R. Rubinow · 2012 to 2026
$2.8M
Uncovering sex-specific differences in ASH1L-diseaseR21MH136643 · NIMH · BROWN UNIVERSITY · PI LIU, JUDY SHIH-HWA, LIZARRAGA, SOFIA BEATRIZ · 2024 to 2025
$421k
NIGMS NIH HHS P20 GM103499NIGMS NIH HHS P20 GM103641NIMH NIH HHS R01 MH127081NIMH NIH HHS R21 MH136643NIMH NIH HHS T32 MH093315
6 · The paper itself

Abstract

Autism spectrum disorder (ASD) affects 1 in 44 children. Chromatin regulatory proteins are overrepresented among genes that contain high risk variants in ASD. Disruption of the chromatin environment leads to widespread dysregulation of gene expression, which is traditionally thought of as a mechanism of disease pathogenesis associated with ASD. Alternatively, alterations in chromatin dynamics could also lead to dysregulation of alternative splicing, which is understudied as a mechanism of ASD pathogenesis. The anticonvulsant valproic acid (VPA) is a well-known environmental risk factor for ASD that acts as a class I histone deacetylase inhibitor. However, the precise molecular mechanisms underlying defects in human neuronal development associated with exposure to VPA are understudied. To dissect how VPA exposure and subsequent chromatin hyperacetylation influence molecular signatures involved in ASD pathogenesis, we conducted RNA sequencing (RNA-seq) in human cortical neurons that were treated with VPA. We observed that differentially expressed genes (DEGs) were enriched for mRNA splicing, mRNA processing, histone modification and metabolism related gene sets. Furthermore, we observed widespread increases in the number and the type of alternative splicing events. Analysis of differential transcript usage (DTU) showed that exposure to VPA induces extensive alterations in transcript isoform usage across neurodevelopmentally important genes. Finally, we find that DEGs and genes that display DTU overlap with known ASD-risk genes. Altogether, these findings suggest that, in addition to differential gene expression, changes in alternative splicing correlated with alterations in the chromatin environment could act as an additional mechanism of disease in ASD.

Indexed as

Autism Spectrum DisorderPrenatal Exposure Delayed EffectsAlternative SplicingAnimalsChildChromatinDisease Models, AnimalFemaleHumansRNA, MessengerValproic AcidChromatinRNA, MessengerValproic Acid

Identifiers

PMID36621967
PMCPMC10162432
OpenAlexW4313857636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.